Stock Research for OREX

OREX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

OREX Stock Chart & Research Data

The OREX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OREX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OREX Due diligence Resources & Stock Charts

The OREX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OREX Detailed Price Forecast - CNN Money CNN View OREX Detailed Summary - Google Finance
Yahoo View OREX Detailed Summary - Yahoo! Finance Zacks View OREX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View OREX Trends & Analysis - Trade-Ideas Barrons View OREX Major Holders - Barrons
NASDAQ View OREX Call Transcripts - NASDAQ Seeking View OREX Breaking News & Analysis - Seeking Alpha
Spotlight View OREX Annual Report - CompanySpotlight.com OTC Report View OREX OTC Short Report - OTCShortReport.com
TradeKing View OREX Fundamentals - TradeKing Charts View OREX SEC Filings - Bar Chart
WSJ View Historical Prices for OREX - The WSJ Morningstar View Performance/Total Return for OREX - Morningstar
MarketWatch View the Analyst Estimates for OREX - MarketWatch CNBC View the Earnings History for OREX - CNBC
StockMarketWatch View the OREX Earnings - StockMarketWatch MacroAxis View OREX Buy or Sell Recommendations - MacroAxis
Bullish View the OREX Bullish Patterns - American Bulls Short Pains View OREX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View OREX Stock Mentions - StockTwits PennyStocks View OREX Stock Mentions - PennyStockTweets
Twitter View OREX Stock Mentions - Twitter Invest Hub View OREX Investment Forum News - Investor Hub
Yahoo View OREX Stock Mentions - Yahoo! Message Board Seeking Alpha View OREX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for OREX - SECform4.com Insider Cow View Insider Transactions for OREX - Insider Cow
CNBC View OREX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OREX - OTC Markets
Yahoo View Insider Transactions for OREX - Yahoo! Finance NASDAQ View Institutional Holdings for OREX - NASDAQ


Stock Charts

FinViz View OREX Stock Insight & Charts - FinViz.com StockCharts View OREX Investment Charts - StockCharts.com
BarChart View OREX Stock Overview & Charts - BarChart Trading View View OREX User Generated Charts - Trading View


Latest Financial News for OREX

[$$] Pernix, Investor Group Offer $75 Million for Orexigen
Posted on Monday April 23, 2018

The offer, revealed Monday in a filing in U.S. Bankruptcy Court in Wilmington, Del., is subject to higher bids at a court-supervised auction. The deal would include the world-wide rights to anti-obesity drug Contrave. to name the investor group’s acquisition vehicle, Nalpropion Pharmaceuticals Inc., as the stalking horse, or lead bidder, at the auction.


Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company
Posted on Monday April 23, 2018

SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval.  Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers.


[$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors
Posted on Wednesday April 11, 2018

Drugmaker’s sale targets are too easy to hit, creditors committee says


[$$] Firm Retention Summary: Orexigen Therapeutics Inc.
Posted on Thursday March 29, 2018

This is a summary of a request from Orexigen Therapeutics Inc. to hire Morris Nichols Arsht & Tunnell LLP as Delaware bankruptcy co-counsel, filed March 23 with the U.S. Bankruptcy Court in Wilmington, ...


Enter a stock symbol to view the stock details.